Literature DB >> 8434708

Stage I renal cell carcinoma. A clinicopathologic study of 82 cases.

A B Gelb1, R B Shibuya, L M Weiss, L J Medeiros.   

Abstract

Stage has been established as the most important predictor of prognosis in renal cell carcinoma. The predictive value of other morphologic features is less well established. Therefore, in this study we assessed morphologic parameters in 82 Robson stage I renal cell carcinomas. Insufficient numbers of T1 lesions were present in this series to permit a confident comparison of Robson staging with the Union Internationale Contre le Cancer-American Joint Committee on Cancer TNM (tumor, node, metastasis) staging. Morphologic parameters--including size, character of cytoplasm, nuclear grade, and pelvic invasion--were studied. Both univariate survival analysis and multivariate or tree-structured survival analysis (TSSA) were employed, with disease-free survival and actuarial survival as end points. Nuclear grade was the most important predictor of prognosis in stage I neoplasms by TSSA. Nuclear grade greater than 2 correlated with significantly shorter survival (p = 0.018). Stage I tumors measuring less than 5.0 cm by survival analysis (or 6.0 cm by TSSA) were associated with improved disease-free survival (p = 0.040), although TSSA indicated that the effect was pronounced only in low-grade neoplasms. The character of cell cytoplasm was not independent of nuclear grade (Kruskal-Wallis test, p = 0.028). The contingency table indicated disproportionate numbers of grade 4 mixed cell tumors, grade 3 granular cell tumors, and low-grade clear cell tumors. By TSSA, younger patients with low-grade but larger tumors had a poor clinical outcome. Elderly patients with high-grade tumors had the worst overall survival. None of the other clinical parameters or architectural pattern correlated with survival or disease-free survival. When nuclear grade was combined with tumor size and age at diagnosis in a decision tree, patients with stage I neoplasms were separated into favorable, intermediate, and poor prognosis groups.

Entities:  

Mesh:

Year:  1993        PMID: 8434708     DOI: 10.1097/00000478-199303000-00008

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  7 in total

1.  [The WHO/ISUP grading system for renal carcinoma].

Authors:  H Moch
Journal:  Pathologe       Date:  2016-07       Impact factor: 1.011

2.  Elevated content of p53 protein in the absence of p53 gene mutations as a possible prognostic marker for human renal cell tumors.

Authors:  G Chemeris; A Loktinov; A Rempel; M Schwarz; P Bannasch
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

3.  Comparison of grading systems for estimating the prognosis of renal cell carcinoma.

Authors:  A Usubütün; M C Uygur; A Ayhan; C Toklu; A Sahin; H Ozen; S Ruacan
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

4.  Impact of histology on the treatment outcome of metastatic or recurrent renal cell carcinoma.

Authors:  J Wu; G Caliendo; X P Hu; J P Dutcher
Journal:  Med Oncol       Date:  1998-04       Impact factor: 3.064

5.  Renal cell carcinoma: correlation of CT findings with nuclear morphologic grading in 100 tumors.

Authors:  B A Birnbaum; M A Bosniak; G A Krinsky; D Cheng; J Waisman; M M Ambrosino
Journal:  Abdom Imaging       Date:  1994 May-Jun

6.  Grade-dependent proteomics characterization of kidney cancer.

Authors:  Bertrand Perroud; Tatz Ishimaru; Alexander D Borowsky; Robert H Weiss
Journal:  Mol Cell Proteomics       Date:  2009-01-21       Impact factor: 5.911

7.  Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy.

Authors:  Rajesh R Singh; Paari Murugan; Lalit R Patel; Horatiu Voicu; Suk-Young Yoo; Tadeusz Majewski; Meenakshi Mehrotra; Khalida Wani; Nizar Tannir; Jose A Karam; Eric Jonasch; Christopher G Wood; Chad J Creighton; L Jeffrey Medeiros; Russell R Broaddus; Pheroze Tamboli; Keith A Baggerly; Kenneth D Aldape; Bogdan Czerniak; Rajyalakshmi Luthra; Kanishka Sircar
Journal:  Mod Pathol       Date:  2015-06-26       Impact factor: 7.842

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.